Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Pmv Pharmaceuticals Inc's Business Segments
Pmv Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Member
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | - | - |
Description of Pmv Pharmaceuticals Inc
PMV Pharmaceuticals Inc is a clinical-stage biotechnology company focused on discovering and developing small molecule drugs that target p53, a tumor-suppressor protein that plays a key role in preventing the development and progression of cancer. The company was founded in 2013 by Dr. Arnold Levine and is headquartered in Cranbury, New Jersey.
PMV Pharma's lead product candidate, PMV-01, is a small molecule that restores the activity of mutant p53 proteins, which are found in over 50% of all human cancers. PMV Pharma is developing PMV-01 for the treatment of a variety of cancers, including ovarian, colorectal, breast, and lung cancers. PMV-01 has completed Phase 1 clinical trials and is currently in Phase 2 clinical trials.
The company has also developed a proprietary drug discovery platform called R-x Discovery, which uses high throughput screening and medicinal chemistry to identify and optimize small molecule drug candidates that target p5 Through this platform, PMV Pharma has identified several preclinical drug candidates that it plans to advance into clinical trials.
PMV Pharma has raised over $300 million in funding to date from a variety of sources, including venture capital firms, strategic investors, and public markets. The company went public in June 2020 and is traded on the NASDAQ under the ticker symbol PMVP.
The company is led by a team of experienced biotech executives, including CEO and President David Mack, who has over 20 years of experience in the pharmaceutical industry. PMV Pharma's board of directors includes several distinguished scientists and business leaders, including Dr. Arnold Levine, the company's founder and a professor of oncology at the Institute for Advanced Study in Princeton, New Jersey.
Overall, PMV Pharmaceuticals Inc is a leading biotech company that is focused on developing innovative cancer therapies that target p53, a key tumor-suppressor protein. With its proprietary drug discovery platform and experienced leadership team, PMV Pharma is well-positioned to make significant contributions to the field of cancer research and treatment in the years to come.
PMV Pharma's lead product candidate, PMV-01, is a small molecule that restores the activity of mutant p53 proteins, which are found in over 50% of all human cancers. PMV Pharma is developing PMV-01 for the treatment of a variety of cancers, including ovarian, colorectal, breast, and lung cancers. PMV-01 has completed Phase 1 clinical trials and is currently in Phase 2 clinical trials.
The company has also developed a proprietary drug discovery platform called R-x Discovery, which uses high throughput screening and medicinal chemistry to identify and optimize small molecule drug candidates that target p5 Through this platform, PMV Pharma has identified several preclinical drug candidates that it plans to advance into clinical trials.
PMV Pharma has raised over $300 million in funding to date from a variety of sources, including venture capital firms, strategic investors, and public markets. The company went public in June 2020 and is traded on the NASDAQ under the ticker symbol PMVP.
The company is led by a team of experienced biotech executives, including CEO and President David Mack, who has over 20 years of experience in the pharmaceutical industry. PMV Pharma's board of directors includes several distinguished scientists and business leaders, including Dr. Arnold Levine, the company's founder and a professor of oncology at the Institute for Advanced Study in Princeton, New Jersey.
Overall, PMV Pharmaceuticals Inc is a leading biotech company that is focused on developing innovative cancer therapies that target p53, a key tumor-suppressor protein. With its proprietary drug discovery platform and experienced leadership team, PMV Pharma is well-positioned to make significant contributions to the field of cancer research and treatment in the years to come.
PMV Pharmaceuticals Inc: Comprehensive Overview
Segment Overview
PMV Pharmaceuticals Inc is a clinical-stage biopharmaceutical company positioned within the oncology segment of the pharmaceutical industry. The company focuses on the development of precision oncology medicines specifically aimed at treating various forms of cancer characterized by genetic abnormalities. This precision approach allows PMV to target cancers that are driven by specific mutations or pathways, optimizing therapeutic effectiveness and improving patient outcomes.
Product Development
PMV Pharmaceuticals is focused on pioneering two key product candidates, which aim to address substantial unmet medical needs in cancer treatment:
1. PC14586:
- Description: PC14586 is a small-molecule oral inhibitor targeting the p53-MDM2/MDMX interaction. The p53 protein is a crucial tumor suppressor, and its deregulation is implicated in a high percentage of human tumors.
- Mechanism of Action: By inhibiting the interaction between MDM2/MDMX and p53, PC14586 aims to restore p53 function, allowing for transcriptional regulation of genes involved in apoptosis, cell cycle arrest, and DNA repair.
- Indications: This product is being developed for multiple solid tumors and hematologic malignancies, making it a versatile candidate in the oncology landscape.
- Clinical Status: PC14586 has demonstrated promising results in preclinical studies, showing efficacy against tumors with mutations in the p53 gene and offering hope where existing therapies fall short.
2. PC12022:
- Description: PC12022 is another small-molecule oral inhibitor specifically targeting IRAK4, a kinase involved in immune signaling pathways that can contribute to the cancerous phenotype in various tumors.
- Mechanism of Action: By inhibiting IRAK4, this candidate aims to modulate the immune response and potentially reduce tumor growth by impacting inflammation-related pathways that foster cancer progression.
- Indications: Similar to PC14586, PC12022 is being explored for use in multiple solid tumors and hematologic cancers, aiming to address the resistance often seen with current oncology therapies.
- Clinical Status: The ongoing preclinical and clinical development indicates the potential for PC12022 to offer new treatment options to patients with difficult-to-treat cancers.
Services Offered
PMV Pharmaceuticals Inc’s core services revolve around the research-based development of precision oncology therapies, which include:
- Research and Development: PMV conducts extensive preclinical and clinical research to ensure its product candidates meet safety and efficacy standards essential for regulatory approval. The R&D efforts are underscored by a commitment to innovative methodologies and state-of-the-art technologies in tumor biology and therapeutic discovery.
- Clinical Trials: The company actively engages in organizing and conducting clinical trials for its product candidates. These trials are structured to evaluate the safety, tolerability, pharmacokinetics, and efficacy of new treatments in diverse patient populations.
- Regulatory Affairs: PMV navigates the complex regulatory landscape to secure approvals for its drug candidates. This includes preparing documentation and submissions to regulatory bodies, ensuring compliance with industry standards, and participating in discussions regarding clinical trial designs and outcomes.
- Collaborations and Partnerships: The company strategically collaborates with industry partners, academic institutions, and research organizations. These partnerships are essential for fostering innovation, sharing resources, and expediting the development of breakthrough therapies.
- Scientific Expertise: PMV boasts a highly skilled team comprising experienced scientists, oncologists, and biopharma professionals dedicated to the mission of improving cancer treatment. Their combined expertise helps guide the direction of product development and ensures the application of cutting-edge research practices.
Conclusion
PMV Pharmaceuticals Inc represents a strong commitment to advancing precision oncology through the development of targeted therapies aimed at significant genetic drivers of cancer. With its focus on innovative product candidates like PC14586 and PC12022, alongside robust research and development services, PMV is poised to contribute meaningfully to the future of cancer treatment. The company’s collaborative approach further enhances its capability to introduce novel therapies that aim to improve patient outcomes and life quality for those battling cancer.
Segment Overview
PMV Pharmaceuticals Inc is a clinical-stage biopharmaceutical company positioned within the oncology segment of the pharmaceutical industry. The company focuses on the development of precision oncology medicines specifically aimed at treating various forms of cancer characterized by genetic abnormalities. This precision approach allows PMV to target cancers that are driven by specific mutations or pathways, optimizing therapeutic effectiveness and improving patient outcomes.
Product Development
PMV Pharmaceuticals is focused on pioneering two key product candidates, which aim to address substantial unmet medical needs in cancer treatment:
1. PC14586:
- Description: PC14586 is a small-molecule oral inhibitor targeting the p53-MDM2/MDMX interaction. The p53 protein is a crucial tumor suppressor, and its deregulation is implicated in a high percentage of human tumors.
- Mechanism of Action: By inhibiting the interaction between MDM2/MDMX and p53, PC14586 aims to restore p53 function, allowing for transcriptional regulation of genes involved in apoptosis, cell cycle arrest, and DNA repair.
- Indications: This product is being developed for multiple solid tumors and hematologic malignancies, making it a versatile candidate in the oncology landscape.
- Clinical Status: PC14586 has demonstrated promising results in preclinical studies, showing efficacy against tumors with mutations in the p53 gene and offering hope where existing therapies fall short.
2. PC12022:
- Description: PC12022 is another small-molecule oral inhibitor specifically targeting IRAK4, a kinase involved in immune signaling pathways that can contribute to the cancerous phenotype in various tumors.
- Mechanism of Action: By inhibiting IRAK4, this candidate aims to modulate the immune response and potentially reduce tumor growth by impacting inflammation-related pathways that foster cancer progression.
- Indications: Similar to PC14586, PC12022 is being explored for use in multiple solid tumors and hematologic cancers, aiming to address the resistance often seen with current oncology therapies.
- Clinical Status: The ongoing preclinical and clinical development indicates the potential for PC12022 to offer new treatment options to patients with difficult-to-treat cancers.
Services Offered
PMV Pharmaceuticals Inc’s core services revolve around the research-based development of precision oncology therapies, which include:
- Research and Development: PMV conducts extensive preclinical and clinical research to ensure its product candidates meet safety and efficacy standards essential for regulatory approval. The R&D efforts are underscored by a commitment to innovative methodologies and state-of-the-art technologies in tumor biology and therapeutic discovery.
- Clinical Trials: The company actively engages in organizing and conducting clinical trials for its product candidates. These trials are structured to evaluate the safety, tolerability, pharmacokinetics, and efficacy of new treatments in diverse patient populations.
- Regulatory Affairs: PMV navigates the complex regulatory landscape to secure approvals for its drug candidates. This includes preparing documentation and submissions to regulatory bodies, ensuring compliance with industry standards, and participating in discussions regarding clinical trial designs and outcomes.
- Collaborations and Partnerships: The company strategically collaborates with industry partners, academic institutions, and research organizations. These partnerships are essential for fostering innovation, sharing resources, and expediting the development of breakthrough therapies.
- Scientific Expertise: PMV boasts a highly skilled team comprising experienced scientists, oncologists, and biopharma professionals dedicated to the mission of improving cancer treatment. Their combined expertise helps guide the direction of product development and ensures the application of cutting-edge research practices.
Conclusion
PMV Pharmaceuticals Inc represents a strong commitment to advancing precision oncology through the development of targeted therapies aimed at significant genetic drivers of cancer. With its focus on innovative product candidates like PC14586 and PC12022, alongside robust research and development services, PMV is poised to contribute meaningfully to the future of cancer treatment. The company’s collaborative approach further enhances its capability to introduce novel therapies that aim to improve patient outcomes and life quality for those battling cancer.